Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01561768 | A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults | PHASE2 | COMPLETED | 500 | — | — | Mar 1, 2012 | Jan 1, 2013 | Jul 18, 2013 | 4 | Australia |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Group 3 | EXPERIMENTAL | - |
| Group 4 | EXPERIMENTAL | - |
| Group 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Novavax Quadrivalent vaccine | BIOLOGICAL | Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid |
| Novavax Trivalent vaccine | BIOLOGICAL | Trivalent Dose; intramuscular injection, deltoid |
| cTIV | BIOLOGICAL | Preconfigured dose; intramuscular injection, deltoid |
Inclusion Criteria: 1. Healthy adult male or females, 18-64 years of age 2. Willing and able to give informed consent prior to study enrollment 3. Able to comply with study requirements 4. Women who are not post-menopausal (≥ 50 years of age and at least one year post last menses) or surgically ste...